Anant Pharmaceuticals Pvt. Ltd. was founded in 2005 with the distinct objective of partnering with the pharmaceutical industry in specialized services. Anant, derived from Sanskrit meaning 'Infinite', signifies endless service possibilities for our clients. In the constantly expanding arena of custom synthesis and analytical service firms, we are committed to offering distinctive and tailored services to our clients. Established to provide innovative solutions for research and development teams, we have become a dependable and preferred source for various products such as impurity reference standards and related items. Enanta's approach driven by chemistry and drug discovery capabilities is concentrated on small molecule drugs for the treatment of viral infections and liver diseases including respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV). Enanta has chosen EDP-514, an inhibitor of the HBV core protein, as its initial clinical candidate, which is currently undergoing Phase 1 clinical trials.